Sort   by:  
 Page size 
UnknownPhase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer.
Not available
S-EPMC8259133 | biostudies-literature
UnknownRandomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).
Not available
S-EPMC8462593 | biostudies-literature
UnknownAmyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI.
Not available
S-EPMC4831042 | biostudies-literature
UnknownFractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial.
Not available
S-EPMC4215160 | biostudies-literature
UnknownGenomic, transcriptomic, and protein landscape profile of CFTR and cystic fibrosis.
Not available
S-EPMC7855842 | biostudies-literature
UnknownAbiraterone in metastatic prostate cancer without previous chemotherapy.
Not available
S-EPMC3683570 | biostudies-literature
UnknownSafety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.
Not available
S-EPMC6233779 | biostudies-literature
UnknownBetter verbal memory in women than men in MCI despite similar levels of hippocampal atrophy.
Not available
S-EPMC4831033 | biostudies-literature
UnknownRadium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial.
Not available
S-EPMC7474951 | biostudies-literature
UnknownProspective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer.
Not available
S-EPMC8425833 | biostudies-literature
Sort   by:  
 Page size